Here are the 10-K annual reports from SIGA Technologies, Inc. (SIGA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SIGA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SIGA filings page.
SIGA Technologies describes its biodefense-focused pharmaceutical business built around TPOXX, an antiviral for smallpox and related orthopox viruses, sold mainly to governments. The company’s core U.S. revenue base is a BARDA contract contemplating up to approximately $630 million of payments for oral and IV TPOXX, pediatric and post‑marketing work.
SIGA also reports sales to the U.S. Department of Defense of about $10 million in 2024 and international oral TPOXX revenue of $5.8 million in 2025, versus $23.0 million in 2024. Future growth depends heavily on new U.S. stockpiling contracts and recurring non‑U.S. government demand.
The filing highlights regulatory risk: European and U.K. approvals for Tecovirimat‑SIGA were granted under “exceptional circumstances” and are undergoing annual reassessment after mpox trials (PALM007, STOMP, UNITY) failed to show statistically significant efficacy on primary endpoints. The CHMP is expected to decide in March whether to maintain, modify, suspend, or withdraw indications, which could reduce mpox‑related revenue. SIGA notes a broad global patent estate on TPOXX with key protections extending into the 2030s and an employee base of 49 as of February 13, 2026.